Topical difluprednate monotherapy for uveitic macular edema.
To describe the use of topical difluprednate for the treatment of uveitic macular edema. Retrospective review of 3 consecutive cases of uveitic macular edema. Patients were treated with topical difluprednate monotherapy. All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33). Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.